Lv52
970 积分 2025-12-26 加入
Amylin: Pharmacology, Physiology, and Clinical Potential
15天前
已完结
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
15天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
15天前
已完结
Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor
16天前
已完结
Discovery of Zoldonrasib (RMC-9805), a Potent and Orally Bioavailable RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor for the Treatment of Patients with RAS G12D-Addicted Cancers
16天前
已关闭
Exploiting Bridged Conformations for Precise Molecular Recognition in the Design of KRAS-Selective, Orally Available Macrocyclic Peptides
1个月前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
3个月前
已完结
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
3个月前
已完结
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers
3个月前
已完结
Disrupted molecular glue complex drives RAS inhibitor resistance
3个月前
已完结